probucol has been researched along with Extramembranous Glomerulopathy in 2 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A significant reduction in proteinuria was seen during the probucol treatment (median (range): 6." | 3.71 | Antioxidant treatment of therapy-resistant idiopathic membranous nephropathy with probucol: a pilot study. ( Breiteneder-Geleff, S; Haas, M; Holzer, H; Hörl, WH; Kerjaschki, D; Kramar, R; Mayer, G; Neuweiler, J; Neyer, U; Ratschek, M; Regele, HM; Schneider, B; Wirnsberger, G, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haas, M | 2 |
| Kerjaschki, D | 2 |
| Mayer, G | 2 |
| Wirnsberger, G | 1 |
| Holzer, H | 1 |
| Ratschek, M | 1 |
| Neyer, U | 1 |
| Neuweiler, J | 1 |
| Kramar, R | 1 |
| Schneider, B | 1 |
| Breiteneder-Geleff, S | 1 |
| Regele, HM | 1 |
| Hörl, WH | 1 |
1 review available for probucol and Extramembranous Glomerulopathy
| Article | Year |
|---|---|
Lipid-lowering therapy in membranous nephropathy.
Topics: Glomerulonephritis, Membranous; Humans; Hypolipidemic Agents; Lipid Peroxidation; Probucol | 1999 |
1 other study available for probucol and Extramembranous Glomerulopathy
| Article | Year |
|---|---|
Antioxidant treatment of therapy-resistant idiopathic membranous nephropathy with probucol: a pilot study.
Topics: Adult; Anticholesteremic Agents; Antioxidants; Dose-Response Relationship, Drug; Drug Administration | 2002 |